What Is the Optimal Immune Response to an Ebola Vaccine?

A recombinant Ebola virus vaccine induced predominantly IgM antibody that was associated with neutralizing activity. A booster vaccination did not increase antibody levels.

The outbreak of Ebola virus infection in West Africa in 2014 resulted in more than 10,000 deaths, prompting new efforts to develop a vaccine. A humoral immune response to vaccination is presumably at least partially responsible for protection, but no single assay has been found predictive of candidate Ebola vaccine efficacy. A recombinant vesicular stomatitis virus–based vaccine expressing surface glycoproteins from the Ebola Zaire strain (rVSVΔG-ZEBOV-GP) has been shown to decrease transmission of Ebola virus in humans after close contact.

In the present study, researchers at the U.S. Food and Drug Administration and the National Institute of Allergy and Infectious Diseases examined the antibody response after primary and boosted vaccinatio…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

What Is the Optimal Immune Response to an Ebola Vaccine?

Topics

Reviewing Author